Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 1013220170150020107
Jouranl of the Korean Society of Clinical Toxicology
2017 Volume.15 No. 2 p.107 ~ p.115
In vitro Protective Effects of Glehnia Littoralis on Alpha-amanitin Induced Hepatotoxicity
Kim Bo-Hyun

Sun Kyeong-Hoon
Kim Sun-Pyo
Park Yong-Jin
Abstract
Purpose: Glehnia littoralis have been used for ischemic stroke, phlegm, cough, systemic paralysis, antipyretics and neuralgia. The pharmacological mechanisms of Glehnia littoralis were reported as calcium channel block, coumarin derivatives, anticoagulation, anti-convulsive effect, anti-oxidant and anti-inflammatory effect until now. Alpha-amanitin (¥á-amanitin) is a major toxin from extremely poisonous Amanita fungi. The ¥á-amanitin induced oxidative stress, which may contribute to its severe hepatotoxicity. The aim of this study was to investigate whether Glehnia littoralis ethyl acetate extract (GLEA) has the protective antioxidant effects on ¥á-amanitin -induced hepatotoxicity.

Methods: The human hepatoma cell line HepG2 cells were pretreated in the presence or absence of GLEA (50, 100 and 200 ¥ìg/ml) for 4 hours, then exposed with 60 ¥ìmol/L of ¥á-amanitin for an additional 4 hours. The cell viability was evaluated by MTT method. AST, ALT and LDH production in culture medium and intracellular MDA, GSH and SOD levels were determined.

Results: GLEA (50, 100 and 200 ¥ìg/ml) significantly increased the relative cell viability by 7.11, 9.87 and 14.39%, respectively, and reduced the level of ALT by 10.39%, 34.27% and 52.14%, AST by 9.89%, 15.16%, and 32.84%, and LDH by 15.86%, 22.98% and 24.32% in culture medium, respectively. GLEA could also remarkably decrease the level of MDA and increase the content of GSH and SOD in HepG2 cells.

Conclusion: In vitro model, Glehnia littoralis was effective in limiting hepatic injury after ¥á-amanitin poisoning. It¡¯s antioxidant effect is attenuated by antidotal therapy.
KEYWORD
Alpha-amanitin, Antioxidant, Glehnia littoralis
FullTexts / Linksout information
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed